Motzer RJ, Rini BI, McDermott DF, Aren Frontera O, Hammers HJ, Carducci MA, et al. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Lancet Oncol. 2019;20(10):1370–85. https://doi.org/10.1016/S1470-2045(19)30413-9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Motzer RJ, Penkov K, Haanen J, Rini B, Albiges L, Campbell MT, et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380(12):1103–15. https://doi.org/10.1056/NEJMoa1816047.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380(12):1116–27. https://doi.org/10.1056/NEJMoa1816714.

Article  CAS  PubMed  Google Scholar 

Choueiri TK, Powles T, Burotto M, Escudier B, Bourlon MT, Zurawski B, et al. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2021;384(9):829–41. https://doi.org/10.1056/NEJMoa2026982.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Makker V, Colombo N, Casado Herraez A, Santin AD, Colomba E, Miller DS, et al. Lenvatinib plus pembrolizumab for advanced endometrial cancer. N Engl J Med. 2022;386(5):437–48. https://doi.org/10.1056/NEJMoa2108330.

Article  CAS  PubMed  Google Scholar 

Martins F, Sofiya L, Sykiotis GP, Lamine F, Maillard M, Fraga M, et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol. 2019;16(9):563–80. https://doi.org/10.1038/s41571-019-0218-0.

Article  CAS  PubMed  Google Scholar 

Friedman CF, Proverbs-Singh TA, Postow MA. Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review. JAMA Oncol. 2016;2(10):1346–53. https://doi.org/10.1001/jamaoncol.2016.1051.

Article  PubMed  Google Scholar 

Buchman AL. Side effects of corticosteroid therapy. J Clin Gastroenterol. 2001;33(4):289–94. https://doi.org/10.1097/00004836-200110000-00006.

Article  CAS  PubMed  Google Scholar 

Matsukane R, Suetsugu K, Hata K, Matsuda K, Nakao S, Minami H, et al. Systematic surveillance of immune-related adverse events in clinical practice and impact of subsequent steroid medication on survival outcomes. Int J Clin Oncol. 2023;28(7):860–71. https://doi.org/10.1007/s10147-023-02349-3.

Article  CAS  PubMed  Google Scholar 

Riudavets M, Mosquera J, Garcia-Campelo R, Serra J, Anguera G, Gallardo P, et al. Immune-related adverse events and corticosteroid use for cancer-related symptoms are associated with efficacy in patients with non-small cell lung cancer receiving anti-PD-(L)1 blockade agents. Front Oncol. 2020;10:1677. https://doi.org/10.3389/fonc.2020.01677.

Article  PubMed  PubMed Central  Google Scholar 

Scott SC, Pennell NA. Early use of systemic corticosteroids in patients with advanced NSCLC treated with nivolumab. J Thorac Oncol. 2018;13(11):1771–5. https://doi.org/10.1016/j.jtho.2018.06.004.

Article  PubMed  Google Scholar 

Margolin K, Ernstoff MS, Hamid O, Lawrence D, McDermott D, Puzanov I, et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol. 2012;13(5):459–65. https://doi.org/10.1016/S1470-2045(12)70090-6.

Article  CAS  PubMed  Google Scholar 

Maher VE, Fernandes LL, Weinstock C, Tang S, Agarwal S, Brave M, et al. Analysis of the association between adverse events and outcome in patients receiving a programmed death protein 1 or programmed death ligand 1 antibody. J Clin Oncol. 2019;37(30):2730–7. https://doi.org/10.1200/JCO.19.00318.

Article  CAS  PubMed  Google Scholar 

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47. https://doi.org/10.1016/j.ejca.2008.10.026.

Article  CAS  PubMed  Google Scholar 

Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378(2):158–68. https://doi.org/10.1056/NEJMra1703481.

Article  CAS  PubMed  Google Scholar 

Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018;378(14):1277–90. https://doi.org/10.1056/NEJMoa1712126.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Goodman RS, Johnson DB, Balko JM. Corticosteroids and cancer immunotherapy. Clin Cancer Res. 2023;29(14):2580–7. https://doi.org/10.1158/1078-0432.CCR-22-3181.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mouri A, Kaira K, Yamaguchi O, Hashimoto K, Miura Y, Shiono A, et al. Effect of systemic steroid use for immune-related adverse events in patients with non-small cell lung cancer receiving PD-1 blockade drugs. J Clin Med. 2021;10:16. https://doi.org/10.3390/jcm10163744.

Article  CAS  Google Scholar 

Parakh S, Park JJ, Mendis S, Rai R, Xu W, Lo S, et al. Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases. Br J Cancer. 2017;116(12):1558–63. https://doi.org/10.1038/bjc.2017.142.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Queirolo P, Spagnolo F, Ascierto PA, Simeone E, Marchetti P, Scoppola A, et al. Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases. J Neurooncol. 2014;118(1):109–16. https://doi.org/10.1007/s11060-014-1400-y.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Arbour KC, Mezquita L, Long N, Rizvi H, Auclin E, Ni A, et al. Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer. J Clin Oncol. 2018;36(28):2872–8. https://doi.org/10.1200/JCO.2018.79.0006.

Article  CAS  PubMed  Google Scholar 

Horvat TZ, Adel NG, Dang TO, Momtaz P, Postow MA, Callahan MK, et al. Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center. J Clin Oncol. 2015;33(28):3193–8. https://doi.org/10.1200/JCO.2015.60.8448.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Harmankaya K, Erasim C, Koelblinger C, Ibrahim R, Hoos A, Pehamberger H, Binder M. Continuous systemic corticosteroids do not affect the ongoing regression of metastatic melanoma for more than two years following ipilimumab therapy. Med Oncol. 2011;28(4):1140–4. https://doi.org/10.1007/s12032-010-9606-0.

Article  CAS  PubMed  Google Scholar 

Ishihara H, Nemoto Y, Nakamura K, Ikeda T, Tachibana H, Fukuda H, et al. Prognostic impact of early treatment interruption of nivolumab plus ipilimumab due to immune-related adverse events as first-line therapy for metastatic renal cell carcinoma: a multi-institution retrospective Study. Target Oncol. 2021;16(4):493–502. https://doi.org/10.1007/s11523-021-00825-2.

Article  PubMed  Google Scholar 

Ishihara H, Takagi T, Kondo T, Homma C, Tachibana H, Fukuda H, et al. Association between immune-related adverse events and prognosis in patients with metastatic renal cell carcinoma treated with nivolumab. Urol Oncol. 2019;37(6):355. https://doi.org/10.1016/j.urolonc.2019.03.003.

Article  CAS  Google Scholar 

Mesti T, Grašič Kuhar C, Ocvirk J. Biomarkers for outcome in metastatic melanoma in first line treatment with immune checkpoint inhibitors. Biomedicines. 2023;11:3. https://doi.org/10.3390/biomedicines11030749.

Article  CAS  Google Scholar 

Ikeda T, Ishihara H, Nemoto Y, Tachibana H, Fukuda H, Yoshida K, et al. Prognostic impact of immune-related adverse events in metastatic renal cell carcinoma treated with nivolumab plus ipilimumab. Urol Oncol. 2021;39(10):735. https://doi.org/10.1016/j.urolonc.2021.05.012.

Article  CAS  Google Scholar 

Bai X, Hu J, Betof Warner A, Quach HT, Cann CG, Zhang MZ, et al. Early use of high-dose glucocorticoid for the management of irAE is associated with poorer survival in patients with advanced melanoma treated with anti-PD-1 Monotherapy. Clin Cancer Res. 2021;27(21):5993–6000. https://doi.org/10.1158/1078-0432.Ccr-21-1283.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kartolo A, Deluce J, Holstead R, Hopman W, Lenehan J, Baetz T. Impact of baseline corticosteroids on immunotherapy efficacy in patients with advanced melanoma. J Immunother. 2021;44(4):167–74. https://doi.org/10.1097/cji.0000000000000360.

Article  CAS  PubMed  Google Scholar 

Ishihara H, Nemoto Y, Nakamura K, Tachibana H, Fukuda H, Yoshida K, et al. Comparison of the impact of immune-related adverse events due to immune checkpoint inhibitor dual combination therapy and immune checkpoint inhibitor plus tyrosine kinase inhibitor combination therapy in patients with advanced renal cell carcinoma. Target Oncol. 2023;18(1):159–68. https://doi.org/10.1007/s11523-022-00940-8.

Article  PubMed  Google Scholar